Safety Data and Beneficial Effects of the Combined Oral Contraceptive Ethinylestradiol 0.03 mg/Chlormadinone Acetate 2 mg (Belara®): A 13-Cycle, Observational Study in Routine Clinical Practice

Author： Pushparajah Daphnee S.  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.31, Iss.2, 2011-02, pp. : 121-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Contraceptive Efficacy and Tolerability of Chlormadinone Acetate 2mg/ Ethinylestradiol 0.03mg (Belara): Results of a Post-Marketing Surveillance Study

By Schramm G.   Steffens D.  

Clinical Drug Investigation, Vol. 22, Iss. 4, 2002-01 ,pp. : 221-231

Adis International

Access to resources Recommend Favorite

Extended Cycles with the Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg: Pooled Analysis of Data from Three Large-Scale, Non-Interventional, Observational Studies

By Göretzlehner Gunther  

Clinical Drug Investigation, Vol. 31, Iss. 4, 2011-04 ,pp. : 269-277

Adis International

Access to resources Recommend Favorite

Six-Month Evaluation of the Benefits of the Low-Dose Combined Oral Contraceptive Chlormadinone Acetate 2 mg/Ethinylestradiol 0.03 mg in Young Women: Results of the Prospective, Observational, Non-Interventional, Multicentre TeeNIS Study

By Anthuber Sabine  

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 211-220

Adis International

Access to resources Recommend Favorite

User Satisfaction with the Combined Oral Contraceptive Drospirenone 3 mg/Ethinylestradiol 20 μg (Yasminelle®) in Clinical Practice: A Multi-Country, Questionnaire-Based Study

By Short Mary  

Clinical Drug Investigation, Vol. 29, Iss. 3, 2009-02 ,pp. : 153-159

Adis International

Access to resources Recommend Favorite

Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20µg and Drospirenone 3mg

By Cibula D.  

Clinical Drug Investigation, Vol. 26, Iss. 3, 2006-01 ,pp. : 143-150

Adis International

Access to resources Recommend Favorite